109 related articles for article (PubMed ID: 36750540)
81. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients].
Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ
Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904
[TBL] [Abstract][Full Text] [Related]
82. Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18.
Jenison SA; Yu XP; Valentine JM; Galloway DA
J Virol; 1991 Mar; 65(3):1208-18. PubMed ID: 1704924
[TBL] [Abstract][Full Text] [Related]
83. [Detection of E2 gene polymorphism of human papillomavirus type 16 in patients with cervical lesions and cervical cancer].
Qiu F; Yuan L; Huang X
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Oct; 32(10):1503-6. PubMed ID: 23076195
[TBL] [Abstract][Full Text] [Related]
84. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.
Yin FF; Wang N; Bi XN; Yu X; Xu XH; Wang YL; Zhao CQ; Luo B; Wang YK
Virol J; 2016 Apr; 13():60. PubMed ID: 27044426
[TBL] [Abstract][Full Text] [Related]
85. Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China.
Wu EQ; Zhang GN; Yu XH; Ren Y; Fan Y; Wu YG; Kong W; Zha X
BMC Cancer; 2008 Jul; 8():202. PubMed ID: 18644159
[TBL] [Abstract][Full Text] [Related]
86. Genetic variation of human papillomavirus type 16 in individual clinical specimens revealed by deep sequencing.
Kukimoto I; Maehama T; Sekizuka T; Ogasawara Y; Kondo K; Kusumoto-Matsuo R; Mori S; Ishii Y; Takeuchi T; Yamaji T; Takeuchi F; Hanada K; Kuroda M
PLoS One; 2013; 8(11):e80583. PubMed ID: 24236186
[TBL] [Abstract][Full Text] [Related]
87. Diagnostic value of high-risk human papillomavirus viral load on cervical lesion assessment and ASCUS triage.
Wang M; Hou B; Wang X; Han L; Shi Y; Zhang Y; Zhang L; Liu L; Jin F; Zhang Y
Cancer Med; 2021 Apr; 10(7):2482-2488. PubMed ID: 33682355
[TBL] [Abstract][Full Text] [Related]
88. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.
Galati L; Combes JD; Le Calvez-Kelm F; McKay-Chopin S; Forey N; Ratel M; McKay J; Waterboer T; Schroeder L; Clifford G; Tommasino M; Gheit T
Microbiol Spectr; 2022 Apr; 10(2):e0148021. PubMed ID: 35225653
[TBL] [Abstract][Full Text] [Related]
89. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
Fu Xi L; Schiffman M; Ke Y; Hughes JP; Galloway DA; He Z; Hulbert A; Winer RL; Koutsky LA; Kiviat NB
Int J Cancer; 2017 Apr; 140(8):1747-1756. PubMed ID: 28052328
[TBL] [Abstract][Full Text] [Related]
90. LncRNA HOTAIR promotes proliferation and inhibits apoptosis by sponging miR-214-3p in HPV16 positive cervical cancer cells.
Zhou Y; Wang Y; Lin M; Wu D; Zhao M
Cancer Cell Int; 2021 Jul; 21(1):400. PubMed ID: 34320988
[TBL] [Abstract][Full Text] [Related]
91. The relationship between HPV16 and HPV18 viral load and cervical lesions progression.
Botezatu A; Socolov D; Goia CD; Iancu IV; Ungureanu C; Huică I; Anton G
Roum Arch Microbiol Immunol; 2009; 68(3):175-82. PubMed ID: 20361539
[TBL] [Abstract][Full Text] [Related]
92. Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage.
Marongiu L; Godi A; Parry JV; Beddows S
BMC Cancer; 2014 May; 14():384. PubMed ID: 24885011
[TBL] [Abstract][Full Text] [Related]
93. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia.
Flores R; Papenfuss M; Klimecki WT; Giuliano AR
Int J Cancer; 2006 Mar; 118(5):1187-93. PubMed ID: 16152619
[TBL] [Abstract][Full Text] [Related]
94. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
95. HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China.
Qiu AD; Wu EQ; Yu XH; Jiang CL; Jin YH; Wu YG; Chen Y; Chen Y; Shan YM; Zhang GN; Fan Y; Zha X; Kong W
Gynecol Oncol; 2007 Jan; 104(1):77-85. PubMed ID: 16970982
[TBL] [Abstract][Full Text] [Related]
96. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Roden RB; Greenstone HL; Kirnbauer R; Booy FP; Jessie J; Lowy DR; Schiller JT
J Virol; 1996 Sep; 70(9):5875-83. PubMed ID: 8709207
[TBL] [Abstract][Full Text] [Related]
97. Retraction Note: Detection of HPV16 viral load in L2 gene as a related predictor of cervical cancer among women in Dhi-Qar province by qRT-PCR.
Jalil AT; Khan MUF; Muhammed HA; Kawen AA; Saeed BQ; Karevskiy A
Mol Biol Rep; 2023 Apr; 50(4):3971. PubMed ID: 36750540
[No Abstract] [Full Text] [Related]
98. Detection of HPV16 viral load in L2 gene as a related predictor of cervical cancer among women in Dhi-Qar province by qRT-PCR.
Jalil AT; Khan MUF; Muhammed HA; Kawen AA; Saeed BQ; Karevskiy A
Mol Biol Rep; 2022 Dec; 49(12):11847-11853. PubMed ID: 36214947
[TBL] [Abstract][Full Text] [Related]
99. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
100. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance.
Trevisan A; Schlecht NF; Ramanakumar AV; Villa LL; Franco EL; The Ludwig-McGill Study Group
J Gen Virol; 2013 Aug; 94(Pt 8):1850-1857. PubMed ID: 23677791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
